- Home
- RA vs STOK Comparison
RA vs STOK Comparison
Compare RA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- STOK
- Stock Information
- Founded
- RA 2016
- STOK 2014
- Country
- RA United States
- STOK United States
- Employees
- RA N/A
- STOK N/A
- Industry
- RA Investment Managers
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- RA Finance
- STOK Health Care
- Exchange
- RA Nasdaq
- STOK Nasdaq
- Market Cap
- RA 740.2M
- STOK 721.4M
- IPO Year
- RA N/A
- STOK 2019
- Fundamental
- Price
- RA $13.22
- STOK $12.10
- Analyst Decision
- RA
- STOK Strong Buy
- Analyst Count
- RA 0
- STOK 7
- Target Price
- RA N/A
- STOK $21.40
- AVG Volume (30 Days)
- RA 280.8K
- STOK 562.4K
- Earning Date
- RA 01-01-0001
- STOK 11-05-2024
- Dividend Yield
- RA 14.73%
- STOK N/A
- EPS Growth
- RA N/A
- STOK N/A
- EPS
- RA N/A
- STOK N/A
- Revenue
- RA N/A
- STOK $16,742,999.00
- Revenue This Year
- RA N/A
- STOK $103.04
- Revenue Next Year
- RA N/A
- STOK N/A
- P/E Ratio
- RA N/A
- STOK N/A
- Revenue Growth
- RA N/A
- STOK 81.08
- 52 Week Low
- RA $11.89
- STOK $4.09
- 52 Week High
- RA $17.32
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- RA 35.41
- STOK 45.91
- Support Level
- RA $13.40
- STOK $11.80
- Resistance Level
- RA $13.49
- STOK $14.39
- Average True Range (ATR)
- RA 0.08
- STOK 0.83
- MACD
- RA -0.03
- STOK -0.02
- Stochastic Oscillator
- RA 0.00
- STOK 23.96
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities (collectively, Real Asset Companies and Issuers). The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.